Comparison of the efficacy of Dexmedetomidine versus Ketamine as an adjunct to Ropivacaine for Scalp nerve block during Awake craniotomy surgery- A Randomised Controlled Trial
Authors:
Open Access
- 18 June 2026
- journal article
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Abstract
Scalp nerve block (SNB) is an established technique for effective analgesia during awake craniotomy, but its analgesic duration is limited when local anesthetics are used alone. Adjuvants such as dexmedetomidine and ketamine may enhance block efficacy, though direct comparative evidence remains limited. This prospective trial randomized forty-six adult patients undergoing elective awake craniotomy to receive SNB with 0.5% ropivacaine with dexmedetomidine 1 µg/kg (Group RD, n = 23) or ketamine 0.5 mg/kg (Group RK, n = 23). The primary outcome was the time to request the first rescue analgesia. Secondary outcomes included onset of sensory blockade, postoperative pain scores, rescue analgesic consumption, hemodynamic variables, respiratory depression, psychosis, and time to discharge from the postoperative ward. The time to first rescue analgesia was significantly longer in Group RK compared with Group RD (18.67 [17.08-19.00] vs. 14.67 [12.92-15.08] hours; P = 0.001). Group RK demonstrated significantly lower postoperative pain scores at 6,10, and 16 h postoperatively (P < 0.004) and reduced consumption of rescue analgesia (P < 0.001). The onset of sensory blockade was comparable with a higher incidence of respiratory depression in Group RD (P = 0.02). Group RK showed higher intraoperative heart rate and mean arterial pressure, though values remained within clinically acceptable limits. Ketamine (0.5 mg/kg) as an adjuvant to ropivacaine for SNB in awake craniotomy provides longer postoperative analgesia and reduced rescue analgesic requirements compared with dexmedetomidine, with a lower incidence of respiratory depression. Dexmedetomidine offers superior hemodynamic attenuation to noxious stimuli. Larger multicenter studies are warranted to establish optimal adjuvant selection. Clinical Trials Registry-India (CTRI): CTRI/2024/01/061259, https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTY2NDQ=&Enc=&userName= Date of registration: 09/01/2024 Date of enrolment of first patient: 15/01/2024 Principal Investigator: Dr Ankur Luthra.Keywords
This publication has 20 references indexed in Scilit:
- Comparison of the efficacy of dexmedetomidine and dexamethasone as adjuvants to ropivacaine for scalp nerve block in patients undergoing awake craniotomy: A randomized controlled trialClinical Neurology and Neurosurgery, 2025
- The efficacy and safety of dexmedetomidine as an adjuvant to local anaesthetics in scalp nerve blocks in patients undergoing craniotomy: A systematic review and meta-analysis of randomized controlled trialsClinical Neurology and Neurosurgery, 2025
- Opioid-free anesthesia in craniotomy – Current evidence and Gaps in implementationBrain and Spine, 2025
- Comparative Evaluation of analgesic efficacy of ketamine and magnesium sulfate as adjuvants to bupivacaine for scalp block in supratentorial Craniotomy: A Randomized, Double-Blind clinical studyJournal of Clinical Neuroscience, 2025
- Efficacy and safety of ketamine as an adjuvant to regional anesthesia: A systematic review and meta-analysis of randomized controlled trialsJournal of Clinical Anesthesia, 2024
- Dexmedetomidine as an adjuvant to scalp block in patients undergoing elective craniotomy: A prospective randomized controlled trialClinical Neurology and Neurosurgery, 2023
- Ketamine; history and role in anesthetic pharmacologyNeuropharmacology, 2022
- Side effect profiles of different opioids in the perioperative setting: are they different and can we reduce them?British Journal of Anaesthesia, 2019
- Perineural adjuncts for peripheral nerve blockBJA Education, 2019
- Effects of Adding Dexmedetomidine to Levobupivacaine in Axillary Brachial Plexus BlockCurrent Therapeutic Research, 2012